Comprehensive Stock Comparison
Compare Kiniksa Pharmaceuticals, Ltd. (KNSA) vs Can-Fite BioPharma Ltd. (CANF) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | KNSA | 60.1% revenue growth vs CANF's -9.3% |
| Quality / Margins | KNSA | 17.5% net margin vs CANF's -15.7% |
| Stability / Safety | CANF | Beta 0.36 vs KNSA's 0.46 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CANF | +169.9% vs KNSA's +119.4% |
| Efficiency (ROA) | KNSA | 15.5% ROA vs CANF's -114.0%, ROIC 17.1% vs -448.3% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Kiniksa Pharmaceuticals is a biopharmaceutical company that develops and commercializes treatments for inflammatory and autoimmune diseases. It generates revenue primarily from sales of ARCALYST for recurrent pericarditis — its only approved product — with additional income from licensing and collaboration agreements. The company's competitive advantage lies in its targeted pipeline of monoclonal antibodies addressing specific immune pathways with high unmet medical needs.
Can-Fite BioPharma is a clinical-stage biopharmaceutical company developing small molecule drugs targeting inflammatory diseases and cancer. It generates revenue primarily through licensing agreements and milestone payments from partners — with no commercial products yet — as it advances its lead candidates through clinical trials. The company's competitive advantage lies in its proprietary A3 adenosine receptor platform, which targets a novel pathway for treating autoimmune and inflammatory conditions.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
KNSA leads in 4 of 6 categories (Financial Metrics, Valuation Metrics). CANF leads in 1 (Risk & Volatility).
Financial Metrics (TTM)
KNSA is the larger business by revenue, generating $678M annually — 1209.9x CANF's $560,000. KNSA is the more profitable business, keeping 17.5% of every revenue dollar as net income compared to CANF's -15.7%. On growth, KNSA holds the edge at +65.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | KNSAKiniksa Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| RevenueTrailing 12 months | $678M | $560,000 |
| EBITDAEarnings before interest/tax | $79M | -$9M |
| Net IncomeAfter-tax profit | $119M | -$9M |
| Free Cash FlowCash after capex | $136M | -$8M |
| Gross MarginGross profit ÷ Revenue | — | +100.0% |
| Operating MarginEBIT ÷ Revenue | +11.4% | -16.0% |
| Net MarginNet income ÷ Revenue | +17.5% | -15.7% |
| FCF MarginFCF ÷ Revenue | +20.1% | -14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +65.0% | -36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.5% | +36.4% |
Valuation Metrics
| Metric | KNSAKiniksa Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| Market CapShares × price | $3.4B | $14.2B |
| Enterprise ValueMkt cap + debt − cash | $3.2B | $14.2B |
| Trailing P/EPrice ÷ TTM EPS | 59.32x | -4.40x |
| Forward P/EPrice ÷ next-FY EPS est. | 34.78x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 41.03x | — |
| Price / SalesMarket cap ÷ Revenue | 5.01x | 9999.00x |
| Price / BookPrice ÷ Book value/share | 6.19x | 6.34x |
| Price / FCFMarket cap ÷ FCF | 133.57x | — |
Profitability & Efficiency
KNSA delivers a 20.9% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-2 for CANF. KNSA carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to CANF's 0.02x. On the Piotroski fundamental quality scale (0–9), KNSA scores 6/9 vs CANF's 1/9, reflecting solid financial health.
| Metric | KNSAKiniksa Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| ROE (TTM)Return on equity | +20.9% | -2.1% |
| ROA (TTM)Return on assets | +15.5% | -114.0% |
| ROICReturn on invested capital | +17.1% | -4.5% |
| ROCEReturn on capital employed | +14.0% | -108.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 1 |
| Debt / EquityFinancial leverage | 0.02x | 0.02x |
| Net DebtTotal debt minus cash | -$156M | -$5M |
| Cash & Equiv.Liquid assets | $166M | $5M |
| Total DebtShort + long-term debt | $9M | $104,000 |
| Interest CoverageEBIT ÷ Interest expense | — | -580.71x |
Total Returns (with DRIP)
A $10,000 investment in KNSA five years ago would be worth $20,324 today (with dividends reinvested), compared to $2,351 for CANF. Over the past 12 months, CANF leads with a +169.9% total return vs KNSA's +119.4%. The 3-year compound annual growth rate (CAGR) favors KNSA at 51.2% vs CANF's 20.6% — a key indicator of consistent wealth creation.
| Metric | KNSAKiniksa Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| YTD ReturnYear-to-date | +5.9% | +2059.1% |
| 1-Year ReturnPast 12 months | +119.4% | +169.9% |
| 3-Year ReturnCumulative with dividends | +246.0% | +75.3% |
| 5-Year ReturnCumulative with dividends | +103.2% | -76.5% |
| 10-Year ReturnCumulative with dividends | +128.5% | -98.5% |
| CAGR (3Y)Annualised 3-year return | +51.2% | +20.6% |
Risk & Volatility
CANF is the less volatile stock with a 0.36 beta — it tends to amplify market swings less than KNSA's 0.46 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CANF currently trades 96.3% from its 52-week high vs KNSA's 90.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | KNSAKiniksa Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.46x | 0.36x |
| 52-Week HighHighest price in past year | $49.12 | $4.93 |
| 52-Week LowLowest price in past year | $18.26 | $0.17 |
| % of 52W HighCurrent price vs 52-week peak | +90.6% | +96.3% |
| RSI (14)Momentum oscillator 0–100 | 47.3 | 68.6 |
| Avg Volume (50D)Average daily shares traded | 469K | 4.3M |
Analyst Outlook
Wall Street rates KNSA as "Buy" and CANF as "Buy". Consensus price targets imply 52.6% upside for CANF (target: $7) vs 25.1% for KNSA (target: $56).
| Metric | KNSAKiniksa Pharmaceu… | CANFCan-Fite BioPharm… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $55.67 | $7.25 |
| # AnalystsCovering analysts | 10 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.2% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | 100 | 236.47 | +136.5% |
| Can-Fite BioPharma … (CANF) | 100 | 32.52 | -67.5% |
Kiniksa Pharmaceuti… (KNSA) returned +103% over 5 years vs Can-Fite BioPharma … (CANF)'s -76%. A $10,000 investment in KNSA 5 years ago would be worth $20,324 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | $0.00 | $678M | — |
| Can-Fite BioPharma … (CANF) | $169500.00 | $674000.00 | +297.6% |
Kiniksa Pharmaceuticals, Ltd.'s revenue grew from $0M (2016) to $678M (2025) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | -4.1% | 17.5% | +527.7% |
| Can-Fite BioPharma … (CANF) | -40.7% | -11.7% | +71.3% |
Chart 4P/E Ratio History — 3 Years
| Stock | 2022 | 2025 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | 5.8 | 55 | +848.3% |
Kiniksa Pharmaceuticals, Ltd. has traded in a 6x–88x P/E range over 3 years; current trailing P/E is ~59x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Kiniksa Pharmaceuti… (KNSA) | -0.74 | 0.75 | +201.4% |
| Can-Fite BioPharma … (CANF) | -90 | -1.08 | +98.8% |
Kiniksa Pharmaceuticals, Ltd.'s EPS grew from $-0.74 (2016) to $0.75 (2025).
Chart 6Free Cash Flow — 5 Years
Kiniksa Pharmaceuticals, Ltd. generated $25M FCF in 2025 (+117% vs 2021). Can-Fite BioPharma Ltd. generated $-8M FCF in 2024 (+23% vs 2021).
KNSA vs CANF: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is KNSA or CANF a better buy right now?
Kiniksa Pharmaceuticals, Ltd. (KNSA) offers the better valuation at 59.3x trailing P/E (34.8x forward), making it the more compelling value choice. Analysts rate Kiniksa Pharmaceuticals, Ltd. (KNSA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — KNSA or CANF?
Over the past 5 years, Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered a total return of +103.2%, compared to -76.5% for Can-Fite BioPharma Ltd. (CANF). A $10,000 investment in KNSA five years ago would be worth approximately $20K today (assuming dividends reinvested). Over 10 years, the gap is even starker: KNSA returned +128.5% versus CANF's -98.5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — KNSA or CANF?
By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd. (CANF) is the lower-risk stock at 0.36β versus Kiniksa Pharmaceuticals, Ltd.'s 0.46β — meaning KNSA is approximately 29% more volatile than CANF relative to the S&P 500. On balance sheet safety, Kiniksa Pharmaceuticals, Ltd. (KNSA) carries a lower debt/equity ratio of 2% versus 2% for Can-Fite BioPharma Ltd. — giving it more financial flexibility in a downturn.
04Which has better profit margins — KNSA or CANF?
Kiniksa Pharmaceuticals, Ltd. (KNSA) is the more profitable company, earning 17.5% net margin versus -1169.1% for Can-Fite BioPharma Ltd. — meaning it keeps 17.5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KNSA leads at 11.4% versus -1206.2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is KNSA or CANF more undervalued right now?
Analyst consensus price targets imply the most upside for CANF: 52.6% to $7.25.
06Which pays a better dividend — KNSA or CANF?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is KNSA or CANF better for a retirement portfolio?
For long-horizon retirement investors, Kiniksa Pharmaceuticals, Ltd. (KNSA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.46), +128.5% 10Y return). Both have compounded well over 10 years (KNSA: +128.5%, CANF: -98.5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between KNSA and CANF?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.